American Century Companies

American Century Companies’s enGene Therapeutics ENGN Stock Holding History

American Century Companies’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,861	Closed	-$224K	–	2922
2026 Q1	$224K	Buy	32,861 +8,881	+37%	+$79.1K	﹤0.01%	2689
2025 Q4	$217K	Buy	+23,980	New	+$192K	﹤0.01%	2696

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

American Century Companies's ENGN Position: Q2 2026 in Review

American Century Companies sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 32,861 shares — an estimated $224K sold.

American Century Companies first reported a position in ENGN in Q4 2025 and held it in 2 quarters. The position peaked at $224K in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

American Century Companies reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
American Century Companies sold 32,861 enGene Therapeutics shares in Q2 2026, an estimated $224K.
American Century Companies first reported a position in enGene Therapeutics in Q4 2025 and held it in 2 quarters.
American Century Companies's enGene Therapeutics position peaked at $224K in Q1 2026.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.